Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors research hub

A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors CLEER Trial (Chemotherapy Longevity by Evading EGFR Inhibitor Reactions)

This study looks at a new skin cream called HT-001 for skin problems caused by some cancer medicines. It checks if the cream helps reduce side effects like rash and itching, and if it's safe to use.